{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:38:34Z","timestamp":1793893114190,"version":"4.8.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical- and biomarker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenable to novel, reduced-intensity treatments. Previous data suggest sirolimus may rival standard of care prednisone. We conducted a National Heart, Lung, and Blood Institute\/National Cancer Institute-funded Blood and Marrow Transplant Clinical Trials Network multicenter, open-label, randomized phase 2 trial to estimate the difference in day 28 complete response (CR)\/partial response (PR) rates for sirolimus vs prednisone as initial treatment of patients with standard risk (SR) acute GVHD as defined by the Minnesota (MN) GVHD Risk Score and Ann Arbor (AA1\/2) biomarker status. A total of 127 MN-SR patients were randomized (1:1), and 122 were AA1\/2 (sirolimus, n = 58; prednisone, n = 64). Others were AA3 (n = 4), or AA status missing (n = 1). The day 28 CR\/PR rates were similar for sirolimus 64.8% (90% confidence interval [CI], 54.1%-75.5%) vs 73% (90% CI, 63.8%-82.2%) for prednisone. The day 28 rate of CR\/PR with prednisone \u22640.25 mg\/kg\/day was significantly higher for sirolimus than prednisone (66.7% vs 31.7%; P &amp;lt; .001). No differences were detected in steroid-refractory acute GVHD, disease-free survival, relapse, nonrelapse mortality, or overall survival. Sirolimus was associated with reduced steroid exposure and hyperglycemia, reduced grade 2 to 3 infections, improvement in immune suppression discontinuation and patient-reported quality of life, and increased risk for thrombotic microangiopathy. For patients with clinical- and biomarker-based SR acute GVHD, sirolimus demonstrates similar overall initial treatment efficacy as prednisone. In addition, sirolimus therapy spares steroid exposure and allied toxicity, does not compromise long-term survival outcomes, and is associated with improved patient-reported quality of life. This trial was registered at www.clinicaltrials.gov as #NCT02806947.<\/jats:p>","DOI":"10.1182\/blood.2019003125","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T12:43:19Z","timestamp":1574253799000},"page":"97-107","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":85,"title":["Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial"],"prefix":"10.1182","volume":"135","author":[{"given":"Joseph","family":"Pidala","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dawson","sequence":"additional","affiliation":[{"name":"Emmes Corporation, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Martens","sequence":"additional","affiliation":[{"name":"Emmes Corporation, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin M.","family":"Alousi","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Jagasia","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Stem Cell Transplantation, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-5184","authenticated-orcid":false,"given":"Iskra","family":"Pusic","sequence":"additional","affiliation":[{"name":"Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Departments of Pediatrics and Medicine, University of Minnesota Medical School, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, The Icahn School of Medicine at Mount Sinai, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-8688","authenticated-orcid":false,"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Anasetti","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Howard","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Logan","sequence":"additional","affiliation":[{"name":"BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Leifer","sequence":"additional","affiliation":[{"name":"Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa S.","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Emmes Corporation, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"BMT and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Departments of Pediatrics and Medicine, University of Minnesota Medical School, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2020010911591324300_B1","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2020010911591324300_B2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020010911591324300_B3","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V100.12.3877","article-title":"Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia","volume":"100","author":"Gratwohl","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2020010911591324300_B4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","article-title":"Graft-versus-host disease treatment: predictors of survival","volume":"16","author":"Levine","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"2020010911591324300_B5","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1182\/blood-2014-06-577023","article-title":"Phase 3 clinical trial of steroids\/mycophenolate mofetil vs steroids\/placebo as therapy for acute GVHD: BMT CTN 0802","volume":"124","author":"Bola\u00f1os-Meade","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020010911591324300_B6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2020010911591324300_B7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/bbmt.2002.v8.pm12171485","article-title":"Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020010911591324300_B8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2012.09114.x","article-title":"What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score","volume":"157","author":"MacMillan","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2020010911591324300_B9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020010911591324300_B10","article-title":"Validation of Minnesota acute graft-versus-host disease Risk Score [published online ahead of print 18 July 2019]","author":"MacMillan","journal-title":"Haematologica"},{"issue":"1","key":"2020010911591324300_B11","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020010911591324300_B12","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"issue":"2","key":"2020010911591324300_B13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2016-08-735324","article-title":"Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT","volume":"129","author":"Abu Zaid","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020010911591324300_B14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood-2015-03-636753","article-title":"Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment","volume":"126","author":"McDonald","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020010911591324300_B15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2014-06-584789","article-title":"High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation","volume":"125","author":"Ponce","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2020010911591324300_B16","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2008-07-168401","article-title":"Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes","volume":"113","author":"Mielcarek","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2020010911591324300_B17","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2020010911591324300_B18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbmt.2014.10.003","article-title":"Blood and marrow transplant clinical trials network state of the Science Symposium 2014","volume":"21","author":"Appelbaum","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020010911591324300_B19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2011.041236","article-title":"Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids","volume":"96","author":"Pidala","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2020010911591324300_B20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020010911591324300_B21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020010911591324300_B22","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"2020010911591324300_B23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020010911591324300_B24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"issue":"8","key":"2020010911591324300_B25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","article-title":"PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations","volume":"39","author":"Varni","year":"2001","journal-title":"Med Care"},{"issue":"3","key":"2020010911591324300_B26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2020010911591324300_B27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbmt.2010.07.005","article-title":"Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes","volume":"17","author":"Pidala","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020010911591324300_B28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2008.12.488","article-title":"The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients","volume":"15","author":"Hammer","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020010911591324300_B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2020010911591324300_B30","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.bbmt.2011.03.006","article-title":"Variation in management of immune suppression after allogeneic hematopoietic cell transplantation","volume":"17","author":"Pidala","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020010911591324300_B31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bmt.2013.158","article-title":"Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life","volume":"49","author":"Jim","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020010911591324300_B32","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bbmt.2017.01.032","article-title":"Multi-state modeling identifies determinants of successful immune suppression discontinuation: Secondary analysis of BMT CTN 0201 and 0402 trials","volume":"23","author":"Pidala","year":"2017","journal-title":"Biol Blood Marrow Transplantation"},{"key":"2020010911591324300_B33","article-title":"Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation [published online ahead of print 26 September 2019]","author":"Pidala","journal-title":"JAMA Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/2\/97\/1550984\/bloodbld2019003125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/2\/97\/1550984\/bloodbld2019003125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T12:06:01Z","timestamp":1578571561000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/2\/97\/428815\/Randomized-multicenter-trial-of-sirolimus-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003125","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]}}}